EN 
FR 
Reimagined RCT and Expanded Utility of Advanced Quantitative Methods
The life sciences industry is at a critical juncture, facing mounting pressures from increasing trial complexity, rising costs, and evolving regulatory landscapes. At Cytel, we’ve spent nearly 40 years advancing statistical methodologies and biometrics technologies that drive clinical innovation.
Today, we stand at the forefront of a transformative era, where cutting-edge technologies, real-world evidence, and advanced quantitative methods converge to redefine drug development. We are introducing our efforts to reimagine the randomized controlled trial (RCT) and expand its utility, offering life sciences organizations the tools to achieve unparalleled efficiency, adaptability, and impact.
Stay tuned for more to come on this topic. We will be continuously adding new content, including blogs, videos, and in-depth materials, to this page.
Introducing the Book: The Innovation Illusion
In 2024, Cytel undertook a landmark initiative to explore the transformation of clinical trials and the expanded relevance of advanced quantitative methods. Engaging four renowned key opinion leaders (KOLs) and over 30 industry leaders, we captured diverse perspectives on the future of biometrics in life sciences.
Our book, The Innovation Illusion, explores the Reimagined RCT and Expanded Utility of Advanced Quantitative Methods as the central concept. The book examines how biometrics, real-world evidence, and advanced analytics are transforming life sciences. Highlights include the potential of digital twins to replace Phase I trials, adaptive RCTs that streamline Phases II and III, and integrated real-world evidence that redefines patient-centric efficacy and safety.
This forward-looking exploration envisions a future where data science and technology revolutionize clinical research and drug development.
Download your copy of The Innovation Illusion now to dive deeper into these transformative insights.
Related Insights
How is the evidence base evolving in trial research?
Dr Alexander Schacht
Senior Director, Real World Evidence
How do you think the design of early-phase trials will change in the future?
James Matcham
VP of Innovative Statistical Consulting
What role do you think DMCs (DSMBs) will have in future clinical trials?
Walter Boyle
Vice President, DMC Biostatistics
Reach out to our experts
Reach out to our experts and discover how we are empowering life science leaders to realize the full potential of their therapies.
